Skip to main content
Fig. 5 | Systematic Reviews

Fig. 5

From: Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

Fig. 5

a Cumulative rankograms generated by network meta-analysis of treatments for HBeAg-positive population. b Cumulative rankograms generated by network meta-analysis of treatments for HBeAg-negative population. HBeAg hepatitis B e-antigen, VR virologic response, ALT norm normalization of serum alanine aminotransferase, HBeAg loss hepatitis B e-antigen loss, HBeAg sero hepatitis B e-antigen seroconversion, HBsAg loss hepatitis B surface antigen loss, ADV adefovir 10 mg daily, ADV2 adefovir 30 mg daily, ETV entecavir, LAM lamivudine, TBV telbivudine, PLA placebo, TAF tenofovir alafenamide, TDF tenofovir disoproxil fumarate; ADVTBV, ETVTDF, LAMADV, LAMADV1, LAMADV2, and LAMTBV code for different combinations of antiviral agents with full details in Additional file 3

Back to article page